Research & Development
USFDA grants breakthrough therapy designation to Celgene's Pomalyst
15 May 2019 -

It was reported yesterday that the US Food and Drug Administration (USFDA) has granted breakthrough therapy designation to United States-based Celgene's Pomalyst (pomalidomide) intended for the treatment of HIV.

The designation has been granted for the product to treat patients with HIV-positive Kaposi sarcoma who have earlier received systemic chemotherapy, in addition to patients with HIV-negative Kaposi's sarcoma.

Pomalyst is one of the firm's IMiD agents for the treatment of some blood cancers. It is a thalidomide analogue indicated, in combination with dexamethasone, to treat patients with multiple myeloma who have received at least two prior therapies including lenalidomide and proteasome inhibitor.

Login
Username:

Password:


Related Headlines

Body Vision Medical wins US FDA clearance for LungVision 2.0 System for accurate access in pulmonary nodules

FDA Approves Broadened Indication for Xeomin as First-Line Treatment for Blepharospasm in Adult Patients

Celgene Corp. Announces Pomalyst Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma

FDA Grants Orphan Drug Designation to Ayala's AL101 for Potential Treatment of Adenoid Cystic Carcinoma

CEL-SCI Presents New Data for Its LEAPS Vaccine in the Treatment of Rheumatoid Arthritis at the American Association of Immunologists 103rd Annual Meeting

Grail Multi-Cancer Test Granted Breakthrough Device Designation from US FDA

Teva Launches of a Generic Version of Delzicol Delayed-Release Capsules in the United States

New Qiagen Therascreen FGFR Mutation Analysis Companion Diagnostic for Bladder Cancer Now Available from LabCorp

Transgene Receives FDA IND Clearance for Lead MyvacIndividualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia

BioPorto submits FDA application for The NGAL Test in paediatric patients

Vivimed Life Sciences Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid Impurity

Gilead Sciences to Provide Free Truvada for PrEP to Support US Initiative to End the HIV Epidemic

Teva Announces Launch of a Generic Version of Tarceva Tablets in the United States

Bicycle Therapeutics Adds to Clinical Team to Advance Pipeline